Abbott plans to build a $500 million infant formula facility and is ramping up production at other plants as the health care company seeks to increase supplies in the US amid ongoing shortages.
“We are currently in the final stages of determining site location and will work with regulators and other experts to ensure that the facility is state-of-the-art and sets a new standard for infant formula production,” said Robert Ford, Co. its chairman and CEO told investors in an earnings call on Wednesday.
The decision to invest in a new plant comes in response to an analysis that found “this country would benefit from greater manufacturing capacity and redundancy,” Ford said.
Many parents have constantly facedIt began in February when Abbott temporarily closed its largest plant in Sturgis, Michigan, and recalled formulas from several major brands, including Similac.
Plant closes with a federal investigation into four bacterial infections in infants, with the death of two children. The company said its products have not been directly linked to infections, which include various bacterial strains.
FDA inspectors eventually uncovered several breaches at the plant, including bacterial contamination, a leaky roof and lax safety protocols. Production at the Sturgis plant resumed in July, but hiccups related to Abbott’s baby formula continue.
Abbott recalled some formula for babies and toddlers last Friday because the bottles may have faulty caps and not seal completely, possibly spoiling. The latest recall is relatively small and should not spark a repeatEarlier this year, the company said.
According to Abbott, Illinois-based Abbott, the largest US formula manufacturer, “the recall is equivalent to less than a day’s worth of total ounces of infant formula fed in the US and is not expected to affect the overall US infant supply.”
The recall is for certain bottles of 2 fl oz/59 ml of ready-to-feed liquid products for infants and toddlers. Abbott said the formula can cause diarrhea and vomiting if consumed.
Manufactured at Abbott’s manufacturing plant in Columbus, Ohio, the recalled brands include Similac Pro-Total Comfort TM, Similac 360 Total Care, Similac 360 Total Care Sensitive, Similac Special Care 24, Similac Stage 1, Similac NeoSure, Similac Water (Sterilized ) and Pedialyte. electrolyte solution.
The company said that in addition to increasing production throughout its global network, Abbott continues to produce Similac products for hospitals and other health care providers on a separate production line, and infant formula is still available for sale in alternative product sizes at retail stores. is for.
The recalled products were distributed primarily to hospitals, doctors’ offices and retailers in the US, including Puerto Rico. One lot was sent to Barbados, Bermuda, Colombia, the Dominican Republic, Haiti, Jamaica, St. Croix and St. Thomas; And two letters were sent to Canada, Curaçao, Panama, and Trinidad and Tobago.
Customers who have purchased certain recalled formulas should not use it and should instead use the lot number checker on the website to view the list of affected lot numbers at similacrecall.com.